Abstract
Summary
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
The global market for Enbrel (Etanercept) and Biosimilar was estimated to be worth US$ 6350 million in 2025 and is forecast to a readjusted size of US$ 8562.6 million by 2032 with a CAGR of 3.3% during the forecast period 2026-2032
North American market for Enbrel (Etanercept) and Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Asia-Pacific market for Enbrel (Etanercept) and Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Enbrel (Etanercept) and Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The global key companies of Enbrel (Etanercept) and Biosimilar include Pfizer, Amgen, Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In 2025, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Enbrel (Etanercept) and Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Enbrel (Etanercept) and Biosimilar by region & country, by Type, and by Application.
The Enbrel (Etanercept) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2025 as the base year, with history and forecast data for the period from 2021 to 2032. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enbrel (Etanercept) and Biosimilar.
Market Segmentation
By Company
Pfizer
Amgen
Samsung Bioepis
Novartis
3s Bio
Lupin
Segment by Type:
Syringe
Pen
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Enbrel (Etanercept) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Enbrel (Etanercept) and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Enbrel (Etanercept) and Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Enbrel (Etanercept) and Biosimilar was estimated to be worth US$ 6350 million in 2025 and is forecast to a readjusted size of US$ 8562.6 million by 2032 with a CAGR of 3.3% during the forecast period 2026-2032
North American market for Enbrel (Etanercept) and Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Asia-Pacific market for Enbrel (Etanercept) and Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Enbrel (Etanercept) and Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The global key companies of Enbrel (Etanercept) and Biosimilar include Pfizer, Amgen, Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In 2025, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Enbrel (Etanercept) and Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Enbrel (Etanercept) and Biosimilar by region & country, by Type, and by Application.
The Enbrel (Etanercept) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2025 as the base year, with history and forecast data for the period from 2021 to 2032. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enbrel (Etanercept) and Biosimilar.
Market Segmentation
By Company
Pfizer
Amgen
Samsung Bioepis
Novartis
3s Bio
Lupin
Segment by Type:
Syringe
Pen
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Enbrel (Etanercept) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Enbrel (Etanercept) and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Enbrel (Etanercept) and Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Enbrel (Etanercept) and Biosimilar Product Introduction
1.2 Global Enbrel (Etanercept) and Biosimilar Market Size Forecast
1.2.1 Global Enbrel (Etanercept) and Biosimilar Sales Value (2021-2032)
1.2.2 Global Enbrel (Etanercept) and Biosimilar Sales Volume (2021-2032)
1.2.3 Global Enbrel (Etanercept) and Biosimilar Sales Price (2021-2032)
1.3 Enbrel (Etanercept) and Biosimilar Market Trends & Drivers
1.3.1 Enbrel (Etanercept) and Biosimilar Industry Trends
1.3.2 Enbrel (Etanercept) and Biosimilar Market Drivers & Opportunity
1.3.3 Enbrel (Etanercept) and Biosimilar Market Challenges
1.3.4 Enbrel (Etanercept) and Biosimilar Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Enbrel (Etanercept) and Biosimilar Players Revenue Ranking (2025)
2.2 Global Enbrel (Etanercept) and Biosimilar Revenue by Company (2021-2026)
2.3 Global Enbrel (Etanercept) and Biosimilar Players Sales Volume Ranking (2025)
2.4 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Company Players (2021-2026)
2.5 Global Enbrel (Etanercept) and Biosimilar Average Price by Company (2021-2026)
2.6 Key Manufacturers Enbrel (Etanercept) and Biosimilar Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Enbrel (Etanercept) and Biosimilar Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Enbrel (Etanercept) and Biosimilar
2.9 Enbrel (Etanercept) and Biosimilar Market Competitive Analysis
2.9.1 Enbrel (Etanercept) and Biosimilar Market Concentration Rate (2021-2026)
2.9.2 Global 5 and 10 Largest Manufacturers by Enbrel (Etanercept) and Biosimilar Revenue in 2025
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enbrel (Etanercept) and Biosimilar as of 2025)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Syringe
3.1.2 Pen
3.2 Global Enbrel (Etanercept) and Biosimilar Sales Value by Type
3.2.1 Global Enbrel (Etanercept) and Biosimilar Sales Value by Type (2021 VS 2025 VS 2032)
3.2.2 Global Enbrel (Etanercept) and Biosimilar Sales Value, by Type (2021-2032)
3.2.3 Global Enbrel (Etanercept) and Biosimilar Sales Value, by Type (%) (2021-2032)
3.3 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Type
3.3.1 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Type (2021 VS 2025 VS 2032)
3.3.2 Global Enbrel (Etanercept) and Biosimilar Sales Volume, by Type (2021-2032)
3.3.3 Global Enbrel (Etanercept) and Biosimilar Sales Volume, by Type (%) (2021-2032)
3.4 Global Enbrel (Etanercept) and Biosimilar Average Price by Type (2021-2032)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.1.3 Other
4.2 Global Enbrel (Etanercept) and Biosimilar Sales Value by Application
4.2.1 Global Enbrel (Etanercept) and Biosimilar Sales Value by Application (2021 VS 2025 VS 2032)
4.2.2 Global Enbrel (Etanercept) and Biosimilar Sales Value, by Application (2021-2032)
4.2.3 Global Enbrel (Etanercept) and Biosimilar Sales Value, by Application (%) (2021-2032)
4.3 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Application
4.3.1 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Application (2021 VS 2025 VS 2032)
4.3.2 Global Enbrel (Etanercept) and Biosimilar Sales Volume, by Application (2021-2032)
4.3.3 Global Enbrel (Etanercept) and Biosimilar Sales Volume, by Application (%) (2021-2032)
4.4 Global Enbrel (Etanercept) and Biosimilar Average Price by Application (2021-2032)
5 Segmentation by Region
5.1 Global Enbrel (Etanercept) and Biosimilar Sales Value by Region
5.1.1 Global Enbrel (Etanercept) and Biosimilar Sales Value by Region: 2021 VS 2025 VS 2032
5.1.2 Global Enbrel (Etanercept) and Biosimilar Sales Value by Region (2021-2026)
5.1.3 Global Enbrel (Etanercept) and Biosimilar Sales Value by Region (2027-2032)
5.1.4 Global Enbrel (Etanercept) and Biosimilar Sales Value by Region (%), (2021-2032)
5.2 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Region
5.2.1 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Region: 2021 VS 2025 VS 2032
5.2.2 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Region (2021-2026)
5.2.3 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Region (2027-2032)
5.2.4 Global Enbrel (Etanercept) and Biosimilar Sales Volume by Region (%), (2021-2032)
5.3 Global Enbrel (Etanercept) and Biosimilar Average Price by Region (2021-2032)
5.4 North America
5.4.1 North America Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
5.4.2 North America Enbrel (Etanercept) and Biosimilar Sales Value by Country (%), 2025 VS 2032
5.5 Europe
5.5.1 Europe Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
5.5.2 Europe Enbrel (Etanercept) and Biosimilar Sales Value by Country (%), 2025 VS 2032
5.6 Asia Pacific
5.6.1 Asia Pacific Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
5.6.2 Asia Pacific Enbrel (Etanercept) and Biosimilar Sales Value by Country (%), 2025 VS 2032
5.7 South America
5.7.1 South America Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
5.7.2 South America Enbrel (Etanercept) and Biosimilar Sales Value by Country (%), 2025 VS 2032
5.8 Middle East & Africa
5.8.1 Middle East & Africa Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
5.8.2 Middle East & Africa Enbrel (Etanercept) and Biosimilar Sales Value by Country (%), 2025 VS 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Enbrel (Etanercept) and Biosimilar Sales Value Growth Trends, 2021 VS 2025 VS 2032
6.2 Key Countries/Regions Enbrel (Etanercept) and Biosimilar Sales Value
6.2.1 Key Countries/Regions Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.2.2 Key Countries/Regions Enbrel (Etanercept) and Biosimilar Sales Volume, 2021-2032
6.3 United States
6.3.1 United States Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.3.2 United States Enbrel (Etanercept) and Biosimilar Sales Value by Type (%), 2025 VS 2032
6.3.3 United States Enbrel (Etanercept) and Biosimilar Sales Value by Application, 2025 VS 2032
6.4 Europe
6.4.1 Europe Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.4.2 Europe Enbrel (Etanercept) and Biosimilar Sales Value by Type (%), 2025 VS 2032
6.4.3 Europe Enbrel (Etanercept) and Biosimilar Sales Value by Application, 2025 VS 2032
6.5 China
6.5.1 China Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.5.2 China Enbrel (Etanercept) and Biosimilar Sales Value by Type (%), 2025 VS 2032
6.5.3 China Enbrel (Etanercept) and Biosimilar Sales Value by Application, 2025 VS 2032
6.6 Japan
6.6.1 Japan Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.6.2 Japan Enbrel (Etanercept) and Biosimilar Sales Value by Type (%), 2025 VS 2032
6.6.3 Japan Enbrel (Etanercept) and Biosimilar Sales Value by Application, 2025 VS 2032
6.7 South Korea
6.7.1 South Korea Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.7.2 South Korea Enbrel (Etanercept) and Biosimilar Sales Value by Type (%), 2025 VS 2032
6.7.3 South Korea Enbrel (Etanercept) and Biosimilar Sales Value by Application, 2025 VS 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.8.2 Southeast Asia Enbrel (Etanercept) and Biosimilar Sales Value by Type (%), 2025 VS 2032
6.8.3 Southeast Asia Enbrel (Etanercept) and Biosimilar Sales Value by Application, 2025 VS 2032
6.9 India
6.9.1 India Enbrel (Etanercept) and Biosimilar Sales Value, 2021-2032
6.9.2 India Enbrel (Etanercept) and Biosimilar Sales Value by Type (%), 2025 VS 2032
6.9.3 India Enbrel (Etanercept) and Biosimilar Sales Value by Application, 2025 VS 2032
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.1.4 Pfizer Enbrel (Etanercept) and Biosimilar Product Offerings
7.1.5 Pfizer Recent Development
7.2 Amgen
7.2.1 Amgen Company Information
7.2.2 Amgen Introduction and Business Overview
7.2.3 Amgen Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.2.4 Amgen Enbrel (Etanercept) and Biosimilar Product Offerings
7.2.5 Amgen Recent Development
7.3 Samsung Bioepis
7.3.1 Samsung Bioepis Company Information
7.3.2 Samsung Bioepis Introduction and Business Overview
7.3.3 Samsung Bioepis Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.3.4 Samsung Bioepis Enbrel (Etanercept) and Biosimilar Product Offerings
7.3.5 Samsung Bioepis Recent Development
7.4 Novartis
7.4.1 Novartis Company Information
7.4.2 Novartis Introduction and Business Overview
7.4.3 Novartis Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.4.4 Novartis Enbrel (Etanercept) and Biosimilar Product Offerings
7.4.5 Novartis Recent Development
7.5 3s Bio
7.5.1 3s Bio Company Information
7.5.2 3s Bio Introduction and Business Overview
7.5.3 3s Bio Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.5.4 3s Bio Enbrel (Etanercept) and Biosimilar Product Offerings
7.5.5 3s Bio Recent Development
7.6 Lupin
7.6.1 Lupin Company Information
7.6.2 Lupin Introduction and Business Overview
7.6.3 Lupin Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.6.4 Lupin Enbrel (Etanercept) and Biosimilar Product Offerings
7.6.5 Lupin Recent Development
8 Industry Chain Analysis
8.1 Enbrel (Etanercept) and Biosimilar Industrial Chain
8.2 Enbrel (Etanercept) and Biosimilar Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Enbrel (Etanercept) and Biosimilar Sales Model
8.5.2 Sales Channel
8.5.3 Enbrel (Etanercept) and Biosimilar Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer